|Grant Affiliation:||Pantaleo: Poxvirus-Based Vaccine Development|
|Strategy:||Combo: DNA, protein & vector vaccines|
|Study Type:||Pre-Clinical NHP|
|Study Start Date:||2012-06-20|
|Study Made Public:||2016-11-10|
Evaluation on non-human primates of safety and immunogenicity for priming with NYVAC or DNA +/-gp120, followed by protein boosts in combination with either NYVAC or DNA
CAVD 371 (AUP 512) is a non-human primate study comparing DNA/protein and NYVAC/protein prime/boost regimens.
Sign in to see full information about this study and to download study data.